Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease

Kidney and Blood Pressure Research

Volumn 31, Issue 6, 2009, Pages 398-403

  Reiterova J ^a   Obeidova H ^a   Lenicek M ^a   Stekrova J ^a   Merta, M ^a   Maixnerova D ^a   Vitek L ^a   Viklicky O ^a,b   Tesar V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Autosomal dominant polycystic kidney disease; Gene promoter polymorphism; Haplotype; Vascular endothelial growth factor

Indexed keywords

ADENINE; DNA; GUANINE; VASCULOTROPIN;

ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CZECH REPUBLIC; DISEASE COURSE; DNA DETERMINATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57049125221     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000180269     Document Type: Article

References (24)

1. Ravine D, Walker RG, Gibson RN, Forrest SM, Richards RI, Friend K, Sheffield LJ, Kincaid-Smith P, Danks DM: Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease. Lancet 1992;340:1330-1333.
2. Pirson Y, Chauveau D, Grunfeld JP: Autosomal dominant polycystic kidney disease; in Cameron JS, Davison AM, Grunfeld JP, Kerr DNS, Ritz E (eds): Oxford Textbook of Clinical Nephrology. Oxford, Oxford University Press, 1998, pp 2393-2415.
3. Hataboer A, Van Dijk MA, Bogdanova A, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning MH, Ravine D: Comparison of genotypes of polycystic kidney disease types 1 and 2. Lancet 1999;353:103-107.
4. Woo DD, Nguen DK, Khatibi N, Olsen P: Genetic identification of two major modifier loci of polycystic kidney disease progression in PCY mice. J Clin Invest 1997;100:1934-1940.
5. Eremina V, Sood M, Haigh J: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-716.
6. Liu E, Morimoto M, Kitajima S: Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007;18:2094-2104.
7. Lee JE, Park HM, Park HJ: The gene profile of cyst epithelial cells in autosomal dominant polycystic kidney disease patients. J Biochem Mol Biol 2004;37:612-617.
8. Kang DH, Johnson RJ: Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003;12:43-49.
9. Kanellis J, Fraser S, Katerelos M: Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000;278:F905-F915.
10. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doktor RB: VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol 2007;293:C419-C428.
11. Vincenti V, Cassano C, Rochci M: Assignment of the vascular endothelial growth gene to human chromosome 6p21.3. Circulation 1996;93:1493-1495.
12. Tischer E, Mitchell R, Hartman T, Silva M: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-11954.
13. Klagsbrun M, D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259-270.
14. Brogan IJ, Khan N, Isaac K, Hutchinson JA: Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1996;60:1245-1249.
15. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-1235.
16. Shahbazi M, Fryer AA, Pravica V: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002;13:260-264.
17. Awata T, Inoue K, Kurihara S, et al: A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-1639.
18. Brenchley PE, Ralph SA, Summers A: VEGF polymorphisms and renal pathologies. Adv Nephrol Necker Hosp 2002;32:17-23.
19. Summers AM, Coupek BM, Brennan MF: VEGF-460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Transplant 2005;20:2427-2432.
20. Doi K, Noiri E, Fujita T, et al: Non-association of VEGF genetic polymorphisms in promoter -5′ UTR with end-stage renal disease. Nephrol Dial Transplant 2006;21:1124-1125.
21. Štekrová J, Reiterová J, Merta M: PKD2 mutations in a Czech population with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2004;19:1116-1122.
22. Peters DJM, Sandkuyl LA: Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol. Basel, Karger, 1992, vol 97, pp 128-139.
23. Rioux-Leclercq N, Fergelot P, Zerrouki S: Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38:1489-1495.
24. Lambrechts D, Storkebaum E, Morimoto M: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394.